DRD1 and in situ carcinoma: Additionally, in a cohort of patients with preinvasive carcinoma in situ (CIS), we observed increased methylation of the DRD1 promoter in preinvasive lesions that progress to LUSC compared to lesions that regress (Fig. 1D, Fig. S2I).